MedTrace Logo

Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging

NCT03806777 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-01-25

No results posted yet for this study

Summary

This study aims to assess the use of intranasal dexmedetomidine (IN-dex) as a sole agent in aiding the successful completion of a MRI scans in children. Dexmedetomidine, a routinely used anesthetic agent in our institution, has many benefits including sedation with neuro-protective and respiratory sparing features. We will test its effectiveness in completing MRI scans in children that would otherwise be given a full general anesthetic.

Conditions

  • MRI Sedation

Interventions

DRUG

Dexmedetomidine

Highly selective alpha-2 adrenergic agonist with sedative properties.

Sponsors & Collaborators

  • British Columbia Children's Hospital

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Mark Ansermino, FRCA · BC Children's Hospital, Department of Anesthesia

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2020-03-31
Completion
2020-10-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806777 on ClinicalTrials.gov